A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers
Launched by HOFFMANN-LA ROCHE · Aug 16, 2011
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteers, age 18 to 65 years inclusive
- • Intact normal skin without potentially obscuring tattoos, pigmentation, lesion in the area for intended injection
- • A body mass index (BMI) between 18 to 32 kg/m2 inclusive
- Exclusion Criteria:
- • Volunteers with any known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections
- • A history of clinically significant gastrointestinal, renal, hepatic, cardiovascular, or allergic disease
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rennes, , France
Montpellier, , France
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials